Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

(2019) Anna Yordanova et al.   CLINICAL NUCLEAR MEDICINE

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms

(2018) Yaoheng Lu et al.   MEDICINE

The safety of available treatments options for neuroendocrine tumors

(2017) A. Faggiano et al.   Expert Opinion On Drug Safety

Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance

(2017) Michael Scharf et al.   NEUROENDOCRINOLOGY

The role of multimodal treatment in patients with advanced lung neuroendocrine tumors

(2017) Nicola Fazio et al.   Journal of Thoracic Disease

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

(2015) Phillip G. Claringbold et al.   NEUROENDOCRINOLOGY

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

(2014) G. Kong et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18F-FDG PET: Feasibility of a Metabolic Grading System

(2014) S. Ezziddin et al.   JOURNAL OF NUCLEAR MEDICINE

High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation

(2014) H. Bahri et al.   JOURNAL OF NUCLEAR MEDICINE

Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors

(2013) Pamela L. Kunz et al.   PANCREAS

Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors

(2012) Phillip G. Claringbold et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Preparation of Patient Doses of 177Lu-DOTA-TATE Using Indigenously Produced 177Lu: The Indian Experience

(2011) Tapas Das et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

(2011) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

(2010) T. Binderup et al.   CLINICAL CANCER RESEARCH

Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors

(2010) D. Campana et al.   JOURNAL OF NUCLEAR MEDICINE

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

(2010) Aldo Scarpa et al.   MODERN PATHOLOGY

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

(2008) Martijn van Essen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY